YAP1 and prostate carcinoma: Furthermore, in a chemohormonal setting, Matsuda et al. observed that elevated nuclear YAP1 in residual tumor tissue after neoadjuvant docetaxel-based therapy in prostate cancer was an independent predictor of biochemical recurrence [15].